Alnylam Insider Amy Schulman Buys 11,250 Shares, Betting on RNA‑i Growth Amid Stock’s Slump

Insider Buying Spurs Fresh Optimism for Alnylam

On May 13 2026, Amy Schulman—an executive of Alnylam Pharmaceuticals—executed a sizable purchase of 11,250 shares of the company’s common stock at roughly $70.20 each, boosting her post‑transaction holding to 23,211 shares. The purchase, filed under Form 4, came at a time when Alnylam’s share price was trading near $291, a level that has slid modestly over the last week (–0.83 %) but remains well below the 52‑week low of $280.60. Schulman’s action, coupled with a recent options exercise, signals a belief that the stock is undervalued and that the company’s RNA‑i platform will continue to deliver incremental growth.

What Does This Mean for Investors? Schulman’s stake now exceeds 0.06 % of the company’s diluted shares, a sizeable position for a non‑executive insider. The move aligns with a broader pattern of insider buying across the board: while senior executives such as Melissa McLaughlin (HR), Pushkal Garg (R&D), and others have sold sizable blocks, their cumulative sales have been offset by new purchases by other insiders, including Schulman. For price‑sensitive investors, Schulman’s buy is a bullish signal that the company’s recent data from the HELIOS‑B Phase 3 study on Vutrisiran for transthyretin‑related cardiomyopathy has been interpreted as a catalyst for future product approvals. The company’s market cap of $38.99 billion and a high price‑earnings ratio of 72.11 reflect elevated expectations for future revenue streams. If Alnylam can capitalize on the growing demand for RNA‑i therapeutics, the stock could rally, potentially justifying the current price range.

Schulman’s Insider Profile Examining Schulman’s past filings shows a consistent pattern of opportunistic buying. In May 2025 she exercised 1,558 stock options and purchased 775 shares in a single transaction, immediately raising her holdings to 11,961 shares. These trades were executed at a flat price of $0.00, indicating that options were exercised at the strike price and that the shares were subsequently purchased at market value. The 2026 transaction is the first instance of Schulman buying outright at market price, suggesting a shift from exercising options to directly acquiring shares—perhaps to consolidate her position before an anticipated upside.

Market Context and Forward Look Alnylam’s recent clinical announcements—particularly the sustained benefit of Vutrisiran in high‑risk heart‑failure patients—have renewed enthusiasm among specialty‑drug investors. Yet the company remains early‑stage, with a high P/E that could be vindicated only if the pipeline delivers. Schulman’s buying, against a backdrop of high‑profile sell‑offs by other insiders, may be interpreted as a vote of confidence. Investors should monitor the company’s next quarterly earnings for revenue from approved products, as well as any additional data from the DemonsTTRate observational study, to gauge whether the optimistic sentiment translates into concrete financial performance.